CLinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial
- 26 May 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (1), 170-181
- https://doi.org/10.1111/j.1365-2133.2006.07344.x
Abstract
Background Efalizumab (anti‐CD11a), a humanized monoclonal antibody, blocks multiple T‐cell‐dependent functions implicated in the pathogenesis of psoriasis, including T‐cell activation, migration to the skin, reactivation in psoriatic skin and interactions with keratinocytes. Objectives This multinational, randomized, double‐blind, placebo‐controlled, parallel‐group trial was designed to evaluate the safety and efficacy of subcutaneous efalizumab 1·0 mg kg−1 once weekly for 12 weeks compared with placebo in a population that included high‐need patients, defined as those for whom at least two systemic therapies were unsuitable because of lack of efficacy, intolerance or contraindication. Patients/methods Patients with moderate‐to‐severe plaque psoriasis [involvement of ≥ 10% of total body surface area and Psoriasis Area and Severity Index (PASI) ≥ 12·0 at screening] were randomized in a 2 : 1 ratio to receive efalizumab or placebo. The primary efficacy endpoint was the proportion of patients achieving ≥ 75% PASI improvement (PASI‐75 response) at week 12 in the intention‐to‐treat population; secondary endpoints included changes in PASI, static Physician's Global Assessment, Physician's Global Assessment of change from baseline and percentage of body surface area affected. Results We enrolled 793 patients (529 received efalizumab and 264 placebo), including 526 high‐need patients (342 received efalizumab and 184 placebo). Week 12 PASI‐75 rates were 29·5% for efalizumab compared with 2·7% for placebo among high‐need patients (P < 0·0001) and 31·4% for efalizumab compared with 4·2% for placebo in the full study population (P < 0·0001). Results for all secondary efficacy endpoints showed superiority of efalizumab over placebo in both the high‐need and the full populations. Efalizumab demonstrated a favourable safety profile, without evidence of systemic toxicity, in both the high‐need group and the overall study population. Conclusions The efficacy and safety of efalizumab therapy were comparable between high‐need patients and the more general moderate‐to‐severe psoriasis patient population. In view of its demonstrated efficacy and safety profile, efalizumab represents a valuable option for the treatment of adult patients with moderate‐to‐severe plaque psoriasis, including high‐need patients.Keywords
This publication has 23 references indexed in Scilit:
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of ActionDermatology, 2004
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.Journal of Investigative Dermatology, 2000
- Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basisNature Medicine, 1995
- Remote T cell co‐stimulation via LFA‐1/ICAM‐1 and CD2/LFA‐3: Demonstration with immobilized ligand/mAb and implication in monocyte‐mediated co‐stimulationEuropean Journal of Immunology, 1991
- The Role of Adhesion Molecules, Chemotactic Factors, and Cytokines in Inflammatory and Neoplastic Skin Disease—1990 UpdateJournal of Investigative Dermatology, 1990
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.The Journal of Experimental Medicine, 1986
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983